Mind Medicine (mindmed) Stock Earnings Reports

Definium Therapeutics says Q1 2026 marked a strong start to a pivotal year focused on advancing its lead psychedelic-derived candidate DT120 ODT. The company is running four Phase III studies across major depressive disorder (MDD) and generalized anxiety disorder (GAD) with three topline readouts expected soon: Emerge (MDD) later this quarter, and Voyage and Panorama (GAD) in the third quarter. DT120 has Breakthrough Therapy designation for GAD. The Phase III program emphasizes magnitude of effect, safety/tolerability and durability after a single administration (targeting durability to 12 weeks and up to 1 year follow-up in Part B). Sample size re-estimations in Voyage and Panorama increased power to ~99% to detect a 5-point placebo-adjusted difference; Emerge is powered at 80% with clinical meaningfulness considered at ~3 points. The company also plans a PTSD program (Haven) and is advancing DT402 (R-MDMA) in ASD. Commercial strategy targets patients who failed ≥2 prior therapies and high-volume psychiatric prescribers, with a hub support model and payer engagement in progress. Q1 operating spend rose as expected (R&D $41.5M, G&A $17.7M), net loss widened to $77.1M partly driven by mark-to-market warrant revaluation, and the balance sheet shows $373.4M in cash, equivalents and investments—management believes this provides runway into 2028 to cover planned operations and multiple clinical readouts.